What is BARD1 Life Sciences?
BARD1 Life Sciences is a biotechnology firm dedicated to the development of innovative cancer diagnostic and therapeutic products. The company's core technology centers on its proprietary BARD1 platform. Its lead product, the BARD1 Lung Cancer Test, is an investigational non-invasive blood test designed for the early detection of lung cancer. Beyond this, BARD1 Life Sciences is actively researching a promising pipeline of potential diagnostic and therapeutic candidates aimed at addressing critical unmet needs across various cancer types.
How much funding has BARD1 Life Sciences raised?
BARD1 Life Sciences has raised a total of $1.1M across 1 funding round:
Stock Offering
$1.1M
Stock Issuance/Offering (2019): $1.1M, investors not publicly disclosed
What's next for BARD1 Life Sciences?
The substantial enterprise-level funding BARD1 Life Sciences has garnered positions it for accelerated growth and product development. This strategic investment is likely to fuel the advancement of its BARD1 Lung Cancer Test towards commercialization and further expand its research into other oncology indications. The company is poised to leverage this capital to enhance its R&D capabilities, potentially forge new strategic partnerships, and navigate the complex regulatory pathways inherent in bringing novel diagnostics and therapeutics to market.
See full BARD1 Life Sciences company page
